Optibiotix Health Share Discussion Threads

[imnotlong] 07/2/2019 09:07

By the way Diamond, well done on your ‘guaranteed news’ prediction for this week. I’ve never doubted you with your ‘down the pub’ method of getting insight into what’s happening at Opti.

[someuwin] 07/2/2019 09:01

'Chilbiome' would be a great product - One that a few on this board could do with.

[aspex] 07/2/2019 08:54

Maybe but why introduce unnecessary complexity for minimal extra margin (?) when it is a shared agreement.Imagination is so wonderful.

[imnotlong] 07/2/2019 08:46

I think if revenues were expected soon the RNS would have stated that. So I will stick to my view of revenues being some time away.

[shrewdmole] 07/2/2019 08:40

Notlong

Sounds like they just rebadge chilbiome to me so a lot sooner to market!

[rayrac] 07/2/2019 08:26

As long as it doesn’t get put into expensive pots!

[imnotlong] 07/2/2019 07:53

Maybe 12 months before the income stream starts if Biolat have to develop the new product first.

[dire cons] 07/2/2019 07:46

Red thumb for a rns. LOL!

[nobbygnome] 07/2/2019 07:39

More money to the bottom line. Yes maybe not a vast amount but the drip drip of deals all adds up!

[someuwin] 07/2/2019 07:05

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Supply agreement for LPLDL® in the Baltic States

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its 100% owned subsidiary, ProBiotix Health Ltd, has entered into a three-year supply agreement with Biolat JSC ("Biolat") covering the supply of its cholesterol and blood pressure reducing LPLDL® strain in Estonia, Latvia and Lithuania.

The agreement grants Biolat a non-exclusive license to package and commercialise own label capsular food products featuring OptiBiotix's proprietary strain Lactobacillus plantarum LPLDL®, with a view to maximising the financial return for both parties. It also provides mutual commercial commitment with ongoing revenue and reflects the growing confidence in the science behind LPLDL® as a functional ingredient, as well as the growing demand for science based food supplement products in the Eastern European market.

Biolat has over 25 years' experience in the manufacturing and distribution of high quality and scientifically validated innovative natural products. Based in Latvia, it is one of the leading players in pharmacy distribution of these products in the Baltics region.

According to Eurostat (2018), the Baltic Member States record the highest death rates from diseases of the circulatory system in the entire EU, with cardiovascular-related fatalities accounting for 50-60% of all deaths. This is also one of the regions where females have the greatest cardiovascular risk - the proportions of women dying from this cause are up to 20% higher than those for men.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this supply agreement with Biolat, which further reinforces the presence of the LPLDL® in a wide range of products in Eastern Europe, where heart disease is a major public health issue. We decided to partner up with Biolat for their experience in the field of natural products manufacturing and distribution and their knowledge of this geographic area. They also have an outstanding track record of successful product launches leading to long-term revenue generation and growth."

[aspex] 07/2/2019 07:04

Another brick in the wall.

[slartybartfaster] 06/2/2019 21:59

Is someone keeping you up. Lol

[rayrac] 06/2/2019 19:11

Good biased stuff on the rampers only lemming thread...but don’t believe a word of it!

Shouldn’t we have had an rns about the delay with LPLDL from Opti?

£73m mc, based on what? Products that don't work and are too expensive? And remove criticism, posters and damaging videos at all cost?

[riskybusiness1] 06/2/2019 17:00

It's been below & above 150DMA for past few weeks. Should find support on 200DMA tomorrow imo

[nimrod22] 06/2/2019 16:38

SP dropped below the 150 dma

[slartybartfaster] 06/2/2019 16:36

Some good stuff on the troll free

[dire cons] 06/2/2019 14:42

Estimated Study Start Date  :February 1, 2019
Estimated Primary Completion Date  :February 1, 2020
Estimated Study Completion Date  :May 1, 2020

[imnotlong] 06/2/2019 14:32

The latest clinical trial of Lpldl at Roehampton has been put back.

Results not not due now until May 2020. Was previously expected July this year.

[rayrac] 06/2/2019 10:53

I hope they can see the large hole in front of them!

[parob] 06/2/2019 10:35

Rebiotix, who were recently acquired by Ferring Pharmaceuticals Group, have just started following OPTI on twitter. They are a clinical-stage biotechnology company harnessing the power of the human microbiome.

[rayrac] 06/2/2019 10:16

Lower LDL cholesterol by 13.9%...not enough
Lower systolic blood pressure by 5.1%...not enough

[parob] 06/2/2019 09:31

What is LPLDL®?A true breakthrough in innovative health product development, OptiBiotix's Lactobacillus plantarum LPLDL® is a next-generation probiotic that aids elements of cardiovascular and wellbeing.LPLDL® has been shown in randomised, placebo controlled human intervention studies to deliver tangible health benefits, reducing cardiovascular risk factors and supporting overall heart wellness. These include: • Lower total cholesterol by up to 36.7% • Lower LDL cholesterol by up to 13.9% • Increase HDL cholesterol by up to 6.5% • Lower systolic blood pressure by 5.1% • Be completely safe and well tolerated

[nobbygnome] 06/2/2019 07:59

Yes I am on the forum but couldn't work out what I had to do once I had clicked the link 🙄..... I will try again later.